You are here: Industry Insights > prostate cancer

News List

Exelixis initiates phase 3 trial of Cabozantinib/Atezolizumab combo in prostate cancer pharmaceutical-business-review
July 06, 2020
Exelixis, Inc. announced the initiation of CONTACT-02, a global phase 3 pivotal trial of cabozantinib (CABOMETYX) in combination with atezolizumab (TECENTRIQ) in patients with metastatic castration-resistant prostate cancer (CRPC) who have been ...
NICE sticks to Zytiga rejection pharmatimes
June 29, 2020
NICE will not be recommending Janssen's Zytiga (abiraterone acetate) with prednisone or prednisolone plus androgen deprivation therapy (ADT), within its marketing authorisation , for treating newly diagnosed high-risk metastatic ...
Novel prostate cancer drug formulation could improve drug’s efficacy europeanpharmaceuticalreview
June 23, 2020
A new oil-based oral formulation of prostate cancer drug abiraterone acetate could enable a smaller dose of the drug to be effective and reduce possible side effects, a study has shown.
Dr Reddy’s Laboratories launch Abiraterone Acetate Tablets USP in the US expresspharma
June 22, 2020
Dr Reddy’s Laboratories announced the launch of Abiraterone Acetate Tablets USP, 250 mg, a therapeutic equivalent generic version of Zytiga (abiraterone acetate) approved by the US Food and Drug Administration (USFDA).
UK study highlights potential of genetic screening for prostate cancer pharmatimes
June 02, 2020
Findings of pioneering study unveiled at ASCO 2020 show that genetic screening for prostate cancer in GP surgeries could be effective at picking up otherwise undiagnosed cases of the disease in seemingly healthy males.
FDA approves Lynparza (olaparib) for HRR mutated prostate cancer europeanpharmaceuticalreview
May 26, 2020
Lynparza’s approval was based on results from a Phase III clinical trial in which it improved overall survival and progression-free survival in patients with certain prostate cancers.
AstraZeneca-Merck’s Lynparza gets US FDA nod for prostate cancer treatment expresspharma
May 21, 2020
The drug approval by the US regulator is for treating patients with a form of prostate cancer that could not be held back by standard hormone therapy.
Zydus Cadila launches Enzalutamide to treat prostate cancer expresspharma
May 11, 2020
The therapy priced at nearly two-thirds the cost of the currently available products in the market.
ICR welcomes new advanced prostate cancer treatment guideline pharmatimes
May 08, 2020
The Institute of Cancer Research, London, has welcomed approval of targeted hormone therapies enzalutamide and abiraterone as first-line NHS treatments for men with advanced prostate cancer.
Lynparza Demonstrated Overall Survival Benefit for Prostate Cancer in Trial americanpharmaceuticalreview
April 26, 2020
AstraZeneca and Merck announced further positive results from the Phase III PROfound trial of Lynparza (olaparib) in men with metastatic castration-resistant prostate cancer (mCRPC) ...